Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
Lancet Oncol. 2014.
PMID: 24525202
Free article.
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.
Beksac M, Waage A, Bringhen S, Kristinsson SY, Sucak GT, Gimsing P, Lupparelli G, Fıratlı-Tuğlular T, Juliusson G, Turesson I, Palumbo A.
Beksac M, et al. Among authors: lupparelli g.
Acta Haematol. 2015;133(4):372-380. doi: 10.1159/000370023. Epub 2015 Mar 24.
Acta Haematol. 2015.
PMID: 25824293
Free article.
Item in Clipboard
Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia.
Motta I, Consonni D, Stroppiano M, Benedetto C, Cassinerio E, Tappino B, Ranalli P, Borin L, Facchini L, Patriarca A, Barcellini W, Lanza F, Filocamo M, Cappellini MD; Splenomegaly Gaucher group.
Motta I, et al.
Sci Rep. 2021 Jan 28;11(1):2594. doi: 10.1038/s41598-021-82296-z.
Sci Rep. 2021.
PMID: 33510429
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite